TREATMENT OF ADVANCED NON-HODGKINS LYMPHOMAS WITH FAVORABLE HISTOLOGIES - PRELIMINARY-RESULTS OF A PROSPECTIVE TRIAL

Authors:
  • CPC S Portlock
    C S Portlock
  • SRS A Rosenberg
    S A Rosenberg
  • EGE Glatstein
    E Glatstein
  • HKH S Kaplan
    H S Kaplan

  • 1 January 1976
    • journal article
    • research article
    • Vol. 47  (5) , 747-756
    • PMID:769864
Abstract
From July, 1971 to Aug., 1975, 63 previously untreated patients with stage IV non-Hodgkin''s lymphomas with favorable histologies were prospectively randomized to 3 treatment programs: cyclophosphamide, vincristine and prednisone alone (CVP); split course CVP and total lymphoid irradiation (CVP-TLI) or single alkylating agent (SA) therapy. More than 95% of all patients responded to therapy, and pathologically documented complete remissions were achieved in 78.3% of CVP, 65% of CVP-TLI and 55% of SA patients (P > 0.2). The actuarial probability of obtaining a complete remission was the same (> 80%) for SA patients as it was for those receiving CVP or CVP-TLI, but the time required to achieve a complete remission was more prolonged for SA patients (up to 40 mo.). Only 6 (14.3%) complete responders relapsed; the others remained relapse-free for periods of 1-35 mo. There were no statistically significant differences noted among the groups in terms of the probability of disease-free survival or survival, and 82.7% of all patients are alive at 30 mo. (84.6% CVP, 73% CVP-TLI and 90% SA). All 3 treatment programs were highly effective in achieving excellent responses and prolonged disease-free survivals in patients with stage IV non-Hodgkin''s lymphomas with favorable histologies. Over the 4 yr period of study, single agent therapy was associated with as good or better overall survival when compared to the more aggressive treatment programs (CVP and CVP-TLI).